

Data + Perspectives: Investigators Discuss the Effects of Emerging Research on the Care of Patients with Acute Myeloid Leukemia**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Preliminary results from the LACEWING trial evaluating gilteritinib with azacitidine versus azacitidine alone for patients with newly diagnosed acute myeloid leukemia (AML) and a FLT3 mutation who were ineligible for intensive induction chemotherapy demonstrated which of the following clinical outcomes with gilteritinib/azacitidine?**
 - Statistically significant improvement in overall survival
 - No statistically significant improvement in overall survival
- 2. Results of a substudy of the BEAT AML Master Trial demonstrated efficacy with the addition of which agent to enasidenib monotherapy for patients with suboptimal responses?**
 - Azacitidine
 - CC-486
 - CPX-351
 - Magrolimab
- 3. Based on the results of the QUAZAR AML-001 trial, which of the following agents was recently approved by the FDA as maintenance therapy for patients with AML who attain first complete remission (CR) or CR with incomplete blood count recovery after intensive induction chemotherapy and who are not able to complete intensive curative therapy?**
 - CC-486 (oral azacitidine)
 - CPX-351
 - Gemtuzumab
- 4. Which of the following drug types best describes the mechanism of action of magrolimab?**
 - Hypomethylating agent
 - Bcl-2 inhibitor
 - Anti-CD47 monoclonal antibody